JPY 714.0
(3.18%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 241.49 Million JPY | 108.87% |
2022 | 115.61 Million JPY | 26.79% |
2021 | 91.19 Million JPY | 10.58% |
2020 | 82.46 Million JPY | 1346.74% |
2019 | 5.7 Million JPY | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | 96 Million JPY | -43.88% |
2023 Q4 | 241.49 Million JPY | 165.38% |
2023 Q3 | 91 Million JPY | 3.48% |
2023 Q2 | 87.94 Million JPY | 35.55% |
2023 Q1 | 64.88 Million JPY | -43.88% |
2023 FY | 241.49 Million JPY | 108.87% |
2022 Q3 | 90 Million JPY | -26.85% |
2022 Q2 | 123.03 Million JPY | 0.0% |
2022 Q4 | 115.61 Million JPY | 28.47% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
KOHJIN BIO CO LTD | 3.24 Billion JPY | 92.562% |
PRISM BioLab Co.,LTD | 63.41 Million JPY | -280.844% |
GNI Group Ltd. | 26.34 Billion JPY | 99.083% |
Linical Co., Ltd. | 10.3 Billion JPY | 97.656% |
Trans Genic Inc. | 3.81 Billion JPY | 93.666% |
MEDINET Co., Ltd. | 590.2 Million JPY | 59.082% |
Soiken Holdings Inc. | 697.02 Million JPY | 65.353% |
Cytori Cell Research Institute, Inc. | 3.02 Billion JPY | 92.005% |
AnGes, Inc. | 2.78 Billion JPY | 91.342% |
OncoTherapy Science, Inc. | 513.6 Million JPY | 52.98% |
Nxera Pharma Co., Ltd. | 90.38 Billion JPY | 99.733% |
Immuno-Biological Laboratories Co., Ltd. | 353.27 Million JPY | 31.64% |
NanoCarrier Co., Ltd. | 1.64 Billion JPY | 85.363% |
Carna Biosciences, Inc. | 472.35 Million JPY | 48.874% |
CanBas Co., Ltd. | 91.98 Million JPY | -162.531% |
D. Western Therapeutics Institute, Inc. | 1.09 Billion JPY | 77.917% |
RaQualia Pharma Inc. | 809.83 Million JPY | 70.179% |
Chiome Bioscience Inc. | 593.73 Million JPY | 59.326% |
Kidswell Bio Corporation | 4.25 Billion JPY | 94.323% |
PeptiDream Inc. | 29.11 Billion JPY | 99.171% |
Oncolys BioPharma Inc. | 566.5 Million JPY | 57.37% |
Ribomic Inc. | 155.8 Million JPY | -54.996% |
SanBio Company Limited | 2.25 Billion JPY | 89.29% |
Healios K.K. | 11.28 Billion JPY | 97.86% |
BrightPath Biotherapeutics Co., Ltd. | 251.26 Million JPY | 3.889% |
Kubota Pharmaceutical Holdings Co., Ltd. | 369 Million JPY | 34.554% |
StemRIM | 187 Million JPY | -29.143% |
CellSource Co., Ltd. | 677.73 Million JPY | 64.367% |
FunPep Company Limited | 189.32 Million JPY | -27.558% |
Kringle Pharma, Inc. | 596.95 Million JPY | 59.545% |
Stella Pharma Corporation | 1.44 Billion JPY | 83.271% |
TMS Co., Ltd. | 97.68 Million JPY | -147.21% |
Noile-Immune Biotech Inc. | 91.49 Million JPY | -163.948% |
Cuorips Inc. | 200.96 Million JPY | -20.171% |
K Pharma,Inc. | 209.13 Million JPY | -15.475% |
Takara Bio Inc. | 11.42 Billion JPY | 97.885% |
ReproCELL Incorporated | 741.03 Million JPY | 67.411% |
PhoenixBio Co., Ltd. | 917.71 Million JPY | 73.685% |
StemCell Institute Inc. | 3.85 Billion JPY | 93.728% |
Japan Tissue Engineering Co., Ltd. | 908.43 Million JPY | 73.416% |
CellSeed Inc. | 301.04 Million JPY | 19.781% |